DUBLIN – Repare Therapeutics Inc. raised $82.5 million in a series B round to progress its pipeline of precision oncology drugs that target vulnerabilities in cancer cells arising from combinations of synthetically lethal mutations.

Tokyo-based Terumo Corp. already had a formal limited partner relationship with one U.S. venture firm, early medical device-focused, Mountain View, Calif.-based Emergent Medical Partners (EMP) that dates to 2013. Now it has added investment in two more venture firms, Santa Clara, Calif.-based Strategic Healthcare Investment Partners and Boston-based Catalyst Health Ventures.

BEIJING – Multinational antibody specialist Hifibio Therapeutics Inc. said it closed a $67 million series C financing round to advance its drug candidates for cancer and autoimmune disorders.

SEOUL – After a decade of steady increases, venture capital (VC) investments in South Korea's biotech sector are more active. But for the country's strategic financial plan to be sustainable, it will have to further strengthen its science capabilities, according to experts at the Korea Bio Investment Conference (KBIC) last week in Seoul.

SEOUL – South Korea's investors have become very interested in the global cell and gene therapy market. Licensing and M&A deals in the field have been active – a good sign for Korean biopharma firms eager to tap in.

BEIJING – Multinational antibody specialist Hifibio Therapeutics Inc. said it closed a $67 million series C financing round to advance its drug candidates for cancer and autoimmune disorders.

DUBLIN – Gyroscope Therapeutics Ltd. raised £50.4 million (US$60.5 million) to further development of GT-005, its clinical-stage gene therapy for treating dry age-related macular degeneration (AMD), and to advance a second-generation of the subretinal delivery system it gained through its recent merger with Orbit Biomedical Ltd.

LONDON – Achilles Therapeutics Ltd. closed a £100 million (US$120 million) series B round to fund two proof-of-concept studies of its next-generation T-cell immunotherapy in solid tumors, and to build a commercial-scale, fully automated facility for manufacturing the personalized product.